Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03987386 · ClinicalTrials.gov registry record · Phase 3
Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer
A Phase 3 study of Stage III Prostate Cancer AJCC v8 and Stage IVA Prostate Cancer AJCC v8, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 3
- Development phase
- 186
- Enrollment target
- 3
- Study locations
NCT03987386: Active Phase 3 study of Stage III Prostate Cancer AJCC v8 and Stage IVA Prostate Cancer AJCC v8, sponsored by M.D. Anderson Cancer Center.
NCT03987386 is a Phase 3 study of Stage III Prostate Cancer AJCC v8 and Stage IVA Prostate Cancer AJCC v8 that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 186 participants, below the 243-participant average among 28 other Stage III Prostate Cancer AJCC v8 trials with a reported enrollment target (23% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03987386, a Phase 3 study of Stage III Prostate Cancer AJCC v8 and Stage IVA Prostate Cancer AJCC v8, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 186 participants
- Enrollment target
- 3
- Study locations
Study Summary
This phase III trial studies how well hypofractionated radiation therapy works compared to the conventional one in treating patients with prostate cancer. Radiation therapy uses high energy beams to kill tumor cells and shrink tumors. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects.
Primary Outcome
Will be denoted as Tc and Te for conventional and hypo-fractionated arm respectively.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Questionnaire Administration
- RADIATION Radiation Therapy
- RADIATION Hypofractionated Radiation Therapy
Study Locations (3)
Texas
- M D Anderson Cancer Center - Houston
- MD Anderson League City - League City
- MD Anderson in Sugar Land - Sugar Land
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2019-05-30 |
| Est. Completion | 2027-11-01 |
| Phase | Phase 3 |
What the registry record for NCT03987386 still lists
NCT03987386 is an interventional study that assigns participants to a tested intervention. The registered 186 participants enrollment target is mid-sized for trials with a published cap, below the 243-participant average among 28 other Stage III Prostate Cancer AJCC v8 trials with a reported enrollment target (23% lower).
The record links to 4 conditions, with Stage III Prostate Cancer AJCC v8 appearing as the primary indexed condition, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.
NCT03987386 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03987386 about?
NCT03987386 is a clinical study titled "Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer". This phase III trial studies how well hypofractionated radiation therapy works compared to the conventional one in treating patients with prostate cancer. Radiation therapy uses high energy beams to kill tumor cells and shrink tumors. Hypofractionated radiation therapy delivers higher doses of radia...
What is the current status of trial NCT03987386?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 186 participants. The study started on 2019-05-30. Estimated completion is 2027-11-01.
What conditions does trial NCT03987386 study?
This clinical trial studies the following conditions: Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage I Prostate Cancer AJCC v8.
What interventions are being tested in trial NCT03987386?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Radiation Therapy (RADIATION), Hypofractionated Radiation Therapy (RADIATION).
Who is sponsoring clinical trial NCT03987386?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03987386 being conducted?
This trial has 3 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage III Prostate Cancer AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03987386's enrollment target sits among peer trials
186 8th of 28 higher than 20 of 28 other Stage III Prostate Cancer AJCC v8 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stage III Prostate Cancer AJCC v8 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
RECRUITING · Phase 3
-
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial
RECRUITING · Phase 3
-
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
RECRUITING · Phase 3
-
Vitamin D for Prostate Endocrine Therapy
RECRUITING · Phase 3
-
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
RECRUITING · Phase 3
-
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03567889 · 186 participants · Phase 3
Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
- NCT05281471 · 186 participants · Phase 3
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- NCT05405595 · 186 participants · Phase 1
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors
- NCT05762107 · 186 participants · Phase 2
A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI